Good evening, you're tuned in to Markets Desk.
Honda is pulling nearly nine hundred thousand vehicles off the road in a sweeping recall covering Pilot, Ridgeline, Passport, and Acura MDX models spanning model years two thousand fourteen through two thousand twenty three. The issue centers on rear suspension components that may fail under load, potentially causing drivers to lose control. That is a significant liability exposure for American Honda heading into the back half of the year.
Shifting to energy, Brent crude has slipped below ninety dollars a barrel, a level that tends to rattle upstream producers but actually strengthens the case for midstream names. Pipeline operators like Energy Transfer and Enbridge run on volume and contract, not spot price, meaning their cash flows hold up even as the commodity softens. Investors rotating out of pure-play crude exposure may find those toll-road business models increasingly attractive here.
And in biotech, Tectonic Therapeutics has completed enrollment in its Phase two APEX trial for TX forty-five, targeting pulmonary hypertension associated with heart failure with preserved ejection fraction. Completing enrollment is a meaningful de-risking milestone for a clinical-stage company, clearing the path toward readout data that will ultimately determine whether this asset has commercial legs.
That's the tape. Markets Desk, signing off the floor.
